Literature DB >> 8883090

UV-b-induced cataract model in brown-Norway rat eyes combined with preadministration of buthionine sulfoximine.

T Hatano1, M Kojima.   

Abstract

In order to develop a more adequate ultraviolet (UV)-induced cataract model, a combination of l-buthionine sulfoximine (BSO) treatment was applied to experimental animals. A single administration of BSO 4 mmol/kg caused reduced glutathione concentration until experimental day 8. In the 0.067-J/cm2 UV-B irradiation experiment, the light-scattering intensity of the anterior lens cortex of the combination group was significantly higher than that of the other groups during the second week after irradiation commenced. After the fourth experimental week, however, there was no significant difference between the group treated by UV-B alone and the combination group. In the 0.2-J/cm2 UV-B irradiation experiment, anterior polar cataract was seen in the group receiving UV-B alone, as already reported, 6 weeks after starting UV irradiation. Meanwhile, in the combination group, shallow cortical opacity was seen at 26 weeks after the start of experiment in the deeper lenticular layer which was separated from the anterior subcapsular opacity. This anterior shallow cortical opacity seemed to move towards the nuclear region during the time course of the experiment. The results of this experiment suggested that the BSO treatment accelerated cataractogenesis through additional UV-B irradiation. Although more experiments are needed, this model is useful in investigating the connection between UV-B and other cocataractogenic factors in age-related cataract in humans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8883090     DOI: 10.1159/000267957

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  1 in total

1.  Effect of 5-S-GAD on UV-B-induced cataracts in rats.

Authors:  Hiroyoshi Kawada; Masami Kojima; Takahito Kimura; Shunji Natori; Kazuyuki Sasaki; Hiroshi Sasaki
Journal:  Jpn J Ophthalmol       Date:  2009-10-22       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.